Videos
Catalent Talks Cost-Cutting in Biologic Drug Manufacturing
Catalent Talks Cost-Cutting in Biologic Drug Manufacturing
Steve Perry, PE, Sr. Director, Manufacturing Sciences, Catalent Biologics shares insight
04.10.19
The "Meeting Bioprocessing Manufacturing Capacity Demands” panel session at Interphex 2019 focused on solutions for efficient and cost-effective biologic drug manufacturing.
The panelists included:
Michael Felo, Director, Downstream Process Integration, Next Generation Processing, MilliporeSigma
Eric S Langer, President and Managing Partner, BioPlan Associates, Inc.
Rick Morris, Senior Vice President R&D, Pall Biotech, Pall Corporation
Steve Perry, Senior Director, Manufacturing Sciences, Catalent Biologics
Brady Cole, Vice President, Applications, ABEC
Madhu Raghunathan, Product Strategy Leader – BioProcess Hardware, GE Healthcare Life Sciences
The discussion took place on April 3, 11:00 a.m. – noon, innovation stage, #1281. One of the participants, Steve Perry of Catalent Biologics, spoke with Contract Pharma to share the company's thoughts on cost cutting within the biologic manufacturing space, along with industry trends that companies must keep up with to be successful.
Related Searches:
